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Rescue of Migratory Defects of Ehlers–Danlos
Syndrome Fibroblasts In Vitro by Type V Collagen but
not Insulin-Like Binding Protein-1
Simona Viglio1,4, Nicoletta Zoppi2,4, Antonella Sangalli3, Angelo Gallanti1, Sergio Barlati2, Monica Mottes3,
Marina Colombi2 and Maurizia Valli1
Mutations in the genes encoding for type V collagen have been found in the classical type of Ehlers–Danlos
syndrome (EDS); the most common mutations lead to a non-functional COL5A1 allele. We characterized three
skin fibroblast strains derived from patients affected by classical EDS caused by COL5A1 haploinsufficiency. As a
typical clinical hallmark of EDS is the impaired wound healing, we analyzed the repair capability of fibroblasts in
a monolayer wounding assay. The mutant fibroblast strains were unable to move into the scraped area showing
then a marked delay in wound repair. In all the EDS strains, type V collagen was absent in the extracellular space,
also leading to the lack of fibronectin fibrillar network and impairing the expression of a2b1 and a5b1 integrins.
The abnormal integrin pattern inhibited the positive effect of insulin-like growth factor-binding protein-1
on cell migration, whereas the migratory capability remarkably improved in the presence of exogenous type
V collagen.
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INTRODUCTION
Ehlers–Danlos syndrome (EDS) refers to a group of rare
inherited connective tissue disorders characterized by joint
hypermobility, hyperextensible, elastic and fragile skin, tissue
fragility, and impaired wound healing (Steinmann et al., 2002).
It is extremely heterogeneous, and the last clinical classifica-
tion comprehends six different types (Beighton et al., 1998).
The most common type is the classical EDS, comprising former
EDS type I, OMIM 130000, and type II, OMIM 130010. In
about half of the patients with a clinical diagnosis of classical
EDS, mutations in either COL5A1 or COL5A2 gene have been
identified, the majority of them leading to a non-functional
COL5A1 allele (Schwarze et al., 2000; Malfait et al., 2005).
Type V collagen is a minor component of tissues
containing type I collagen, such as skin, bone, cornea,
and blood vessels. Several isoforms exist, the most abundant
and widely distributed is the heterotrimer [a1(V)2a2(V)] that
co-assembles with type I collagen, acting as a regulator of
fibrillar diameter (Birk, 2001). Recent data obtained on
col5a1/ and col5a1þ / mouse embryos (Wenstrup
et al., 2004a, 2006) pointed to a novel role for type V
collagen in the control of type I collagen-rich fibrils
nucleation. Type V collagen plays, therefore, a regulatory
role in the extracellular matrix (ECM) assembly (Andrikopou-
los et al., 1995) and contributes to the development of
functional connective tissues (Chanut-Delalande et al., 2004;
Roulet et al., 2007).
The pathogenic mechanism leading to classical EDS
phenotype is poorly understood. Wenstrup et al. (2004b)
examined matrix deposition in long-term cultures of COL5A1
haploinsufficient EDS cells: total collagen synthesis was
reduced, and significantly fewer fibrils were organized as
compared to control cells. These observations agree with the
data obtained by Zoppi et al. (2004), which showed a
defective organization of collagens and fibronectin in the
ECM, associated with the reduction of a2b1 collagen-binding
integrin and the organization of avb3, instead of a5b1,
fibronectin integrin receptor, in an EDS fibroblast strain,
carrying a COL5A1 missense mutation. Integrins expression is
at least partly controlled by the matrix components (Ruoslahti,
1999); they are involved in cell movement (Huttenlocher
et al., 1996) as well as in angiogenesis and wound repair
(Clark et al., 1996; Stupack and Cheresh, 2004). Moreover,
soluble proteins can affect cell attachment and motility
through binding to integrins and then disrupting fibronecti-
n–integrins or collagen–integrins interactions. For example,
insulin-like growth factor-binding protein-1 (IGFBP-1) stimu-
lates cell migration by binding to a5b1 integrin (Jones et al.,
1993; Irving and Lala, 1995) and improves wound healing in
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a wounding assay (Sala et al., 2005) and in animal models
(Tsuboi et al., 1995).
In this study, we investigated three COL5A1 haploinsuffi-
cient EDS fibroblast strains to evaluate their behavior in a
wounding assay and their adequacy as tools for testing the
effect on EDS cells migration of potential repairing thera-
peutics. We present evidence that the lack of a fibrillar
matrix and an abnormal expression pattern of integrins in
these cells delay wound repair, which is restored by the
treatment with exogenous type V collagen, but not with
IGFBP-1.
RESULTS AND DISCUSSION
Molecular analysis of EDS fibroblasts and ECM organization
Among the skin biopsies from patients affected by EDS
routinely examined in our laboratories, we selected three
fibroblast strains derived from children (Table 1). In these
probands, all the major diagnostic criteria for classical EDS
were fulfilled and the clinical histories indicated a compar-
able phenotypic expression. Pepsin-digested collagens se-
creted into the medium and retained in the cell layer were
analyzed on SDS/PAGE. In all patients, the electrophoretic
mobility of types I and III collagen was normal. In P-24 and
P-28 patients, the amount of a1(V) chain associated to the
cell layer was decreased, as seen by the lowering of the
a1(V)/type I collagen ratio, whereas in P-32, a1(V) chain was
undetectable (Figure 1a; Table 1).
The COL5A1 null allele test was informative for all three
patients with at least one polymorphic marker. Analysis of the
reverse-transcription PCR (RT-PCR) fragments showed that
the expression of one COL5A1 allele was severely reduced in
all the probands; the deficient allele bands increased after the
cycloheximide treatment of the cells (Figure 1b). Sequence
analysis revealed a single nucleotide deletion in two cases,
P-24 and P-32 (Table 1). In P-28 patient, analysis of the whole
coding sequence plus additional regions (see Materials and
Methods) did not show any plausible causal mutation.
The ECM organization in EDS fibroblasts was analyzed by
immunofluorescence 48 hours after seeding. As previously
observed for missense mutations (Zoppi et al., 2004), the
fibrillar network of type V collagen was missing, conse-
quently preventing fibronectin and type III collagen networks
assembly, strongly reducing a2b1 as well as a5b1 integrins,
and inducing the organization of avb3 integrin patches (data
not shown).
The results reported here highlight the pivotal role of type
V collagen in dermal matrix organization and may contribute
to explain the molecular mechanisms resulting from the
deficiency of type V collagen and leading to classical EDS
clinical phenotype. The different isoforms of type V collagen
may have specific biological functions. The most abundant is
the [a1(V)2a2(V)] heterotrimer, embedded in the type I
collagen fibrils and involved in the regulation of fibrils
diameter. COL5A1 haploinsufficiency is, therefore, a limiting
factor for an adequate production of heterotrimers, hence
compromising the regulatory role in fibrils assembly. The
presence of an increased amount of type V collagen
homotrimers or heterotrimers with unusual chain composi-
tion, which further interfere with the normal ECM organiza-
tion, could be postulated as well.
Monolayer wounding assay
We performed an in vitro wounding assay to investigate a
common feature of our three patients, that is, markedly
Table 1. Summary of the molecular and biochemical
analysis of the classical EDS patients
Probands
Age
(years)1
a1(V)/
collagen I
COL5A1
null allele Mutation
P-24 11 0.11 + c.2657delG [32]
p.Gly886AspfsX188
P-28 6 0.14 + ND
P-32 3 ND + c.1601delC [13]
p.Gly536Ala fsX22
Controls 0.15–0.22
EDS, Ehlers–Danlos syndrome; ND, not determined.
DNA mutation numbering was based on cDNA sequence (NM_000093,
GenBank); +1 corresponds to the A of the ATG translation initiation codon
in the reference sequence.
Exon numbers are indicated in square brackets.
1Age at diagnosis.
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Figure 1. Collagens screening and molecular analysis. (a) Fibroblasts
from control (C) and EDS (P-24, P-28, and P-32) were labeled with tritiated
proline, and collagens were purified from the cell layers, pepsin-digested,
and run on 6% SDS/PAGE. Samples were run on different gels. (b) Analysis
of COL5A1 RT-PCR products: fragments obtained after BslI digestion of
RT-PCR products were run on 2% agarose gel electrophoresis. Products in
lanes marked with ‘’ were obtained from RNA extracted from untreated
cells; products in lanes marked with ‘þ ’ were obtained from RNA
extracted from cycloheximide treated cells. MW marker (M) was the 25 bp
DNA ladder (New England Biolabs, Ipswich, MA). P-24 and control (C)
cells were run on a different gel.
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delayed wound healing. As shown in Figure 2a, at time 0,
immediately after wounding and washing of the scraped
cells, the border between the scraped area and confluent
monolayer was sharp in control fibroblasts, whereas in EDS
cells, it was not so evident and cells appeared partly detached
far beyond the scraping line. After 48 hours of incubation in
the presence of low serum concentration (1%), control cells
had migrated in the acellular area almost reaching con-
fluence, whereas in EDS cells, the picture was substantially
the same as at time 0: cells were very sparse, and even more
disorganized than immediately after scraping and showed a
clear delay in scratch repair.
We evaluated the effect of a soluble protein, IGFBP-1, that
stimulates cell migration by binding a5b1 integrin, performing
a wounding assay in the presence of serum-free medium
containing 40 nM IGFBP-1. IGFBP-1 stimulated the migration
and scratch repair of control fibroblasts, but not of EDS strains
(exemplified by patient P-32 in Figure 2b). The inability of
EDS cells to respond to IGBP-1 treatment was also confirmed
in a transwell system. The migration of control fibroblasts in
the presence of 40 nM IGFBP-1 increased threefold, whereas
the EDS cells were unable to respond to the protein and
migrated even less than the untreated cells (Figure 2c).
Our previous data (Zoppi et al., 2004) had also highlighted
a restoration of ECM organization and integrin pattern when
EDS fibroblasts were cultured in the presence of purified type
V collagen. To evaluate the effect of exogenously added
purified human type V collagen on scratch wound repair,
fibroblasts were grown and scraped in a medium supple-
mented with 5 mgml1 of type V collagen. As seen in
Figure 3, treatment with type V collagen did not modify the
control fibroblasts behavior, but it remarkably improved the
scrape repair of EDS fibroblasts. In the mutant strains,
maintained in the presence of type V collagen, the scraping
line at time 0 hour was sharper than in its absence (Figure 2a),
suggesting a more efficient cell adhesion, and after 48 hours
the EDS fibroblasts migrated as the control fibroblasts, fully
covering the acellular area.
Normal wound healing is a complex highly regulated
process and requires several factors, fibronectin and its a5b1
integrin receptor among others (Greiling and Clark, 1997;
Midwood et al., 2006). The downregulation of a5b1 in EDS
cells does not trigger the correct signaling pathways involved
in the repair or in the response to factors as IGFBP-1
specifically require the signaling via a5b1 integrin. The choice
of therapeutics to improve wound repair in classical EDS
should therefore consider possible integrins involvement in
cellular response. The fibrillar organization of ECM is
necessary for efficient adhesion and migration, and we can
conclude that the delayed scrape repair in EDS fibroblasts is
caused by the concurrence of impaired fibrillar network and
an altered integrin pattern. In fact, culturing EDS fibroblasts
with purified type V collagen, which restores the ECM and
the a5b1 and a2b1 integrins organization, improves wound
repair: the wound does not widen and the cellular migration
is comparable to that of control cells.
In conclusion, this wounding assay may be conveniently
used to test different molecules for their capability to rescue
defective migration of cultured EDS fibroblasts.
MATERIALS AND METHODS
Institutional approval was not required for experiments.
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Figure 2. Wound healing and migration in EDS-C fibroblasts. (a) Confluent fibroblasts were scraped with a rubber policeman (0 hour) and allowed to
migrate into the acellular area for 48 hours (48 hours) in DMEM with 1% fetal bovine serum. (b) Confluent fibroblasts of control and patient P-32 were scraped
as above (0 hour) and allowed to migrate for 48 hours (48 hours) in the presence of 40 nM IGFBP-1. Arrowheads indicate the wound edge. (c) A total of
5 104 fibroblasts were plated as above and allowed to migrate either in the presence of serum-free medium alone () or containing 40 nM IGFBP-1 (þ ).
Values are expressed as percentage of untreated cells.
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Cell cultures, metabolic labeling, and SDS/PAGE analysis
Control human skin fibroblasts were either from Promo-Cell GmbH
(Heidelberg, Germany) or obtained in our laboratories. The EDS
fibroblasts cultures were established from skin explants of patients
after their written informed consent, and grown and maintained in
DMEM with 10% fetal bovine serum (complete medium). Metabolic
labeling of the cells, collagens purification, and analysis were
performed as described previously (Valli et al., 1991). The normal
range of the a1(V)/collagen I ratio, 0.15–0.22, was calculated from
determination of collagen ratios in the control fibroblast strains
carried out for over 2 years.
Detection of COL5A1 null allele
Genomic DNA obtained from cultured fibroblasts was investigated
with four exonic restriction fragment length polymorphism
(Schwarze et al., 2000). Heterozygosity found at the genomic level
for a given restriction fragment length polymorphism was re-tested
on RT-PCR products. RNA aliquots were treated with DNase I before
RT-PCR. Total RNA was extracted with Trizol (Invitrogen, Carlsbad,
CA). The haploinsufficient strains were grown for 6 hours in the
presence of 100 mgml1 cycloheximide (Sigma Chemical, St Louis,
MO). RT-PCR was obtained by Superscript and Elongase Enzyme
Mix (Invitrogen). The COL5A1 coding region (exons 1–66) and a
portion of the 30UTR, including the poly(A) signal, were amplified in
eight partially overlapping fragments. For P-28, an additional
genomic region comprising 508 bp of the 50 upstream sequence
plus a large portion of exon 1 was also amplified and sequenced.
Primers sequences are available on request. Automated sequencing
was performed at the BMR Genomics Service (Padova, Italy).
Immunofluorescence analysis
Immunofluorescence analysis was performed as described pre-
viously (Zoppi et al., 2004) with polyclonal anti-fibronectin (Sigma
Aldrich), anti-types I, III, and V collagen antibodies, respectively
(Chemicon International, Temecula, CA), and with mouse anti-a5b1
(clone JBS5), anti-avb3 integrin (clone LM609), anti-a2b1 (clone
BHA2.1) mAbs (Chemicon International). The secondary antibodies
were FITC-conjugated anti-rabbit IgG or TRITC (tetramethylrhoda-
mine isothiocyanate)-conjugated anti-goat IgG and anti-mouse IgG
(Calbiochem-Novabiochem Intl, La Jolla, CA).
Monolayer wounding assay
Cells (30,000 cells per cm2) were plated in 35-mm Petri dishes and
allowed to grow to confluence. The confluent monolayers were
wounded by scraping cells using a rubber policeman to generate an
acellular area. After rinses with phosphate-buffered saline, the
monolayers were examined and photographed under inverted
microscope and incubated for 48 hours either in DMEM with 1%
fetal bovine serum or in serum-free medium containing 40 nM
IGFBP-1. At the end of incubation, cells were examined and
photographed. The plates had been previously marked to ensure that
the same area would be recorded. The wounding assay was
performed also in the presence of exogenous type V collagen. The
cells were grown to confluence in medium supplemented with
5mgml1 type V collagen (Chemicon International). After wounding,
cells were incubated for 48 hours in the same medium and recorded
as above.
Cell migration
The cell migration assay was performed in transwell inserts (8 mm
pore size; Nunc, Roskilde, Denmark): 5 104 fibroblasts were
seeded into the upper well in complete medium and left to adhere
for 4 hours; medium was then changed to serum-free medium
supplemented with 40 nM IGFBP-1, purified from amniotic fluid, in
the upper wells. The lower wells contained 500ml serum-free
medium. Cells were allowed to migrate through the filters for
48 hours. Non-migrating cells were removed from the upper surface
using a cotton swab; cells that had migrated to the bottom surface of
the inserts were fixed and stained with Diff-Quick staining kit
(Medion Diagnostic GmbH, Du¨dingen, Switzerland). Migration was
quantified by counting the stained cells in five non-overlapping
fields using a light microscope fitted with a grid eyepiece. Data are
the means±SD of triplicate wells from two experiments.
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Figure 3. Effect of exogenous type V collagen on wound healing.
Fibroblasts from control and Classical EDS patients were plated and grown to
confluence in complete medium supplemented with 5 mgml1 type V
collagen. After wounding (0 hour) with a rubber policeman, fibroblasts
were allowed to migrate for 48 hours (48 hours) in the presence of 5 mgml1
type V collagen. Arrowheads indicate the wound edge.
1918 Journal of Investigative Dermatology (2008), Volume 128
S Viglio et al.
Wound Assay in Ehlers–Danlos Syndrome Fibroblasts
ACKNOWLEDGMENTS
We thank Sara Labo` for help in preparing the paper and Claudio Esposito for
help in mutation analysis. This work was supported by grants from the Italian
Ministry of University and Research (FIRB, Fondo per gli Investimenti della
Ricerca di Base e Progetti di Ricerca di Interesse Nazionale and Centro di
Eccellenza Innovazione Diagnostica e Terapeutica, University of Brescia, Italy).
REFERENCES
Andrikopoulos K, Liu X, Keene DR, Jaenisch R, Ramirez F (1995) Targeted
mutation in the col5a2 gene reveals a regulatory role for type V collagen
during matrix assembly. Nat Genet 9:31–6
Beighton P, De Paepe A, Steinmann B, Tsipouras P, Wenstrup RJ (1998)
Ehlers–Danlos syndromes: revised nosology, Villefranche 1997.
Am J Med Genet 77:31–7
Birk DE (2001) Type V collagen: heterotypic type I/V collagen interactions in
the regulation of fibril assembly. Micron 32:223–7
Chanut-Delalande H, Bonod-Bidaud C, Cogne S, Malbouyres M, Ramirez F,
Fichard A et al. (2004) Development of a functional skin matrix requires
deposition of collagen V heterotrimers. Mol Cell Biol 24:6049–57
Clark RA, Tonnesen MG, Gailit J, Cheresh DA (1996) Transient functional
expression of alphaVbeta 3 on vascular cells during wound repair.
Am J Pathol 148:1407–21
Greiling D, Clark RA (1997) Fibronectin provides a conduit for fibroblast
transmigration from collagenous stroma into fibrin clot provisional
matrix. J Cell Sci 110:861–70
Huttenlocher A, Ginsberg MH, Horwitz AF (1996) Modulation of cell
migration by integrin-mediated cytoskeletal linkages and ligand-binding
affinity. J Cell Biol 134:1551–62
Irving JA, Lala PK (1995) Functional role of cell surface integrins on human
trophoblast cell migration: regulation by TGF-beta, IGF-II, and IGFBP-1.
Exp Cell Res 217:419–27
Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR (1993)
Insulin-like growth factor binding protein 1 stimulates cell migration and
binds to the alpha 5 beta 1 integrin by means of its Arg–Gly–Asp
sequence. Proc Natl Acad Sci USA 90:10553–7
Malfait F, Coucke P, Symoens S, Loeys B, Nuytinck L, De Paepe A (2005) The
molecular basis of classical Ehlers–Danlos syndrome: a comprehensive
study of biochemical and molecular findings in 48 unrelated patients.
Hum Mutat 25:28–37
Midwood KS, Mao Y, Hsia HC, Valenick LV, Schwarzbauer JE (2006)
Modulation of cell–fibronectin matrix interactions during tissue repair.
J Investig Dermatol Symp Proc 11:73–8
Roulet M, Ruggiero F, Karsenty G (2007) A comprehensive study of the spatial
and temporal expression of the col5a1 gene in mouse embryos: a clue for
understanding collagen V function in developing connective tissues. Cell
Tissue Res 327:323–32
Ruoslahti E (1999) Fibronectin and its integrin receptors in cancer. Adv
Cancer Res 76:1–20
Sala A, Capaldi S, Campagnoli M, Faggion B, Labo` S, Perduca M et al. (2005)
Structure and properties of the C-terminal domain of insulin-like growth
factor-binding protein-1 isolated from human amniotic fluid. J Biol Chem
280:29812–9
Schwarze U, Atkinson M, Hoffman GG, Greenspan DS, Byers PH (2000) Null
alleles of the COL5A1 gene of type V collagen are a cause of the classic
forms of Ehlers–Danlos syndrome (types I and II). Am J Hum Genet
66:1757–65
Steinmann B, Royce PM, Superti-Furga A (2002) The Ehlers–Danlos syndrome.
In: Connective tissue and its inherited disorders (Royce P, Steimann B
eds), New York: Wiley-Liss, 431–523
Stupack DG, Cheresh DA (2004) Integrins and angiogenesis. Curr Top Dev
Biol 64:207–38
Tsuboi R, Shi CM, Sato C, Cox GN, Ogawa H (1995) Co-administration
of insulin-like growth factor (IGF)-I and IGF-binding protein-1
stimulates wound healing in animal models. J Invest Dermatol 104:
199–203
Valli M, Mottes M, Tenni R, Sangalli A, Gomez-Lira M, Rossi A et al.
(1991) A de novo G to T transversion in a pro-alpha 1(I) collagen gene
for a moderate case of osteogenesis imperfecta. Substitution of
cysteine for glycine 178 in the triple helical domain. J Biol Chem 266:
1872–8
Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Chervoneva I, Birk DE (2004a)
Type V collagen controls the initiation of collagen fibril assembly. J Biol
Chem 279:53331–7
Wenstrup RJ, Florer JB, Cole WG, Willing MC, Birk DE (2004b) Reduced
type I collagen utilization: a pathogenic mechanism in COL5A1
haplo-insufficient Ehlers–Danlos syndrome. J Cell Biochem 92:
113–124
Wenstrup RJ, Florer JB, Davidson JM, Phillips CL, Pfeiffer BJ, Menezes DW
et al. (2006) Murine model of the Ehlers–Danlos syndrome: COL5A1
haploinsufficiency disrupts collagen fibril assembly at multiple stages.
J Biol Chem 281:12888–95
Zoppi N, Gardella R, De Paepe A, Barlati S, Colombi M (2004) Human
fibroblasts with mutations in COL5A1 and COL3A1 genes do not
organize collagens and fibronectin in the extracellular matrix, down-
regulate alpha2beta1 integrin, and recruit alphavbeta3 instead of
alpha5beta1 integrin. J Biol Chem 279:18157–68
www.jidonline.org 1919
S Viglio et al.
Wound Assay in Ehlers–Danlos Syndrome Fibroblasts
